Canada markets close in 45 minutes

Aclarion, Inc. (ACON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7302-0.0748 (-9.29%)
As of 03:10PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.8050
Open0.7500
Bid0.7300 x 800
Ask0.7850 x 1000
Day's Range0.7300 - 0.7600
52 Week Range0.3800 - 4.0500
Volume17,396
Avg. Volume38,375
Market Cap5.74M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3600
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Aclarion Announces Alpesh Patel MD MBA as a Key Opinion Leader Physician Advisor

    Marks the eighth advisor to growing KOL program to build strong body of clinical evidence and support US commercialization Aclarion to participate in upcoming SPINEWEEK 2023 Broomfield, CO, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announce

  • ACCESSWIRE

    Aclarion to Present at Third Annual Winter Wonderland - Best Ideas Virtual Investor Conference on February 21st - 24th, 2023

    Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (CLBP), has been invited to present at the Third Annual Winter Wonderland - Best Ideas Virtual Investor conference, which is being held virtually on February 21st - 24th, 2023.

  • GlobeNewswire

    Aclarion Supports Thought Leadership at the 2nd Annual Sonntag Spine Symposium

    NociscanTM is the first evidence-supported SaaS platform to objectively measure discogenic biomarkers for insight into pathological pain. Nociscan provides decision support to help bridge a major diagnostic void. Robert Eastlack, MD will speak to his real-world experience using Nociscan to effectively evaluate CLBP. BROOMFIELD, CO , Feb. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is lev